Turning Point Buys Rights to LaNova's Claudin18.2-Targeting Drug

The agent is Turning Point's first in-licensed product, which is currently undergoing early-stage trials in Claudin18.2-positive advanced solid tumors.

Related Keywords

China ,South Korea ,Athena Countouriotis , ,Turning Point Therapeutics ,Lanova Medicine Claudin ,Greater China ,Shanghai Based Lanova ,San Diego Based Turning Point ,President Athena Countouriotis ,